NCT07219459 2025-10-21
GDFATHERHCC01
CatalYm GmbH
Phase 2 Not yet recruiting
Clinical Trials
4 trialsNCT06232759 2024-06-10
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 2 Completed
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT06059885 2023-09-29
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Beijing 302 Hospital
Phase 2 Unknown